JP2014196370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014196370A5 JP2014196370A5 JP2014149462A JP2014149462A JP2014196370A5 JP 2014196370 A5 JP2014196370 A5 JP 2014196370A5 JP 2014149462 A JP2014149462 A JP 2014149462A JP 2014149462 A JP2014149462 A JP 2014149462A JP 2014196370 A5 JP2014196370 A5 JP 2014196370A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- daily dose
- antiepileptic
- mood stabilizer
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 239000004050 mood stabilizer Substances 0.000 claims description 17
- 229940127237 mood stabilizer Drugs 0.000 claims description 17
- 230000003556 anti-epileptic effect Effects 0.000 claims description 16
- 239000001961 anticonvulsive agent Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 10
- 208000020925 Bipolar disease Diseases 0.000 claims description 9
- 206010015037 epilepsy Diseases 0.000 claims description 9
- 239000003368 psychostimulant agent Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 2
- 229940025084 amphetamine Drugs 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000003723 learning disability Diseases 0.000 claims 2
- 229960001344 methylphenidate Drugs 0.000 claims 2
- 229960000761 pemoline Drugs 0.000 claims 2
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000019749 Eye movement disease Diseases 0.000 claims 1
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 210000001638 cerebellum Anatomy 0.000 claims 1
- 208000030251 communication disease Diseases 0.000 claims 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 1
- -1 etotoin Natural products 0.000 claims 1
- 230000004424 eye movement Effects 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 208000028780 ocular motility disease Diseases 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 229940084026 sodium valproate Drugs 0.000 claims 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical group [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims 1
- 229960001918 tiagabine Drugs 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90004307P | 2007-02-07 | 2007-02-07 | |
| US60/900,043 | 2007-02-07 | ||
| AUPCT/AU2007/000421 | 2007-03-30 | ||
| PCT/AU2007/000421 WO2008095221A1 (en) | 2007-02-07 | 2007-03-30 | Treatment of adhd |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548546A Division JP5586962B2 (ja) | 2007-02-07 | 2008-02-07 | Ａｄｈｄの治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014196370A JP2014196370A (ja) | 2014-10-16 |
| JP2014196370A5 true JP2014196370A5 (https=) | 2015-02-05 |
Family
ID=39681166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548546A Expired - Fee Related JP5586962B2 (ja) | 2007-02-07 | 2008-02-07 | Ａｄｈｄの治療 |
| JP2014149462A Pending JP2014196370A (ja) | 2007-02-07 | 2014-07-23 | Ａｄｈｄの治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548546A Expired - Fee Related JP5586962B2 (ja) | 2007-02-07 | 2008-02-07 | Ａｄｈｄの治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8957099B2 (https=) |
| EP (2) | EP2505197A1 (https=) |
| JP (2) | JP5586962B2 (https=) |
| AU (1) | AU2007346591A1 (https=) |
| ES (1) | ES2426764T3 (https=) |
| WO (2) | WO2008095221A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007346591A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of ADHD |
| MX2011001384A (es) | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
| ES2865504T3 (es) | 2008-10-16 | 2021-10-15 | Univ Johns Hopkins | Procedimientos y composiciones para la mejora de la función cognitiva |
| ES2758554T3 (es) | 2009-12-08 | 2020-05-05 | Univ Case Western Reserve | Aminoácidos gama para tratamiento de trastornos oculares |
| AU2011215870B2 (en) * | 2010-02-09 | 2016-01-28 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EP3335711A1 (en) * | 2010-03-31 | 2018-06-20 | Supernus Pharmaceuticals, Inc. | Formulations of mazindol |
| KR20120021694A (ko) * | 2010-08-13 | 2012-03-09 | 한국과학기술원 | 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 ｔ?타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물 |
| PL220308B1 (pl) * | 2011-06-03 | 2015-10-30 | Kobel Buys Krystyna | Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego |
| WO2013006704A1 (en) * | 2011-07-05 | 2013-01-10 | Hunt Robert Don | Systems and methods for clinical evaluation of psychiatric disorders |
| GB201111712D0 (en) * | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| WO2013039271A1 (ko) * | 2011-09-16 | 2013-03-21 | 한국과학기술원 | 뇌손상에 의한 전두엽 기능장애 모델 동물 및 전두엽 기능장애의 개선용 조성물 |
| WO2013183985A1 (en) * | 2012-06-05 | 2013-12-12 | Erasmus University Medical Center Rotterdam | Method of treating cognitive impairment and compounds for use therein |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| JP6433482B2 (ja) | 2013-03-15 | 2018-12-05 | エージンバイオ， インコーポレイテッド | 認知機能を改善するための方法および組成物 |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| KR101625575B1 (ko) * | 2013-03-21 | 2016-06-13 | 한국과학기술원 | 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 ｔ―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물 |
| EP2886116A1 (en) * | 2013-12-18 | 2015-06-24 | Biocodex | Benzodioxol derivatives for use in the treatment of attention deficit and/or hyperactivity |
| CA2932301A1 (en) * | 2013-12-25 | 2015-07-02 | Fujimoto Co., Ltd. | Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder |
| CN105380935B (zh) * | 2014-09-03 | 2018-04-03 | 长春海悦药业股份有限公司 | 一种丙戊酸钠药物组合物 |
| WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| EP4541420A3 (en) | 2015-07-17 | 2025-06-25 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| WO2017205606A1 (en) * | 2016-05-26 | 2017-11-30 | Ovid Therapeutics Inc. | Methods of treating behavioral syndromes using pipradrol |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| GB202101462D0 (en) * | 2021-02-03 | 2021-03-17 | Sanchez Hector Mario | Combination therapy for treating executive function disorders |
| EP4370114A4 (en) | 2021-07-14 | 2025-12-24 | Mydecine Innovations Group Inc | NEW SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9209599D0 (en) | 1992-05-02 | 1992-06-17 | Fisons Corp | Novel therapy for the treatment of parkinsons disease |
| AR026610A1 (es) | 1999-12-01 | 2003-02-19 | Ucb Sa | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| US6417184B1 (en) * | 2000-09-19 | 2002-07-09 | David M. Ockert | Triple drug therapy for the treatment and prevention of acute or chronic pain |
| WO2003013514A1 (en) * | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
| US8354438B2 (en) * | 2001-08-08 | 2013-01-15 | Michael Chez | Neurological functions |
| CA2459146A1 (en) | 2001-08-30 | 2003-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
| US20040242671A1 (en) | 2001-10-08 | 2004-12-02 | Renee Grimee | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug |
| WO2004002462A2 (en) * | 2002-06-27 | 2004-01-08 | Warner-Lambert Company Llc | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
| WO2004078162A1 (en) | 2003-01-31 | 2004-09-16 | Elan Pharma International Ltd. | Nanoparticulate topiramate formulations |
| MX2007013882A (es) | 2005-05-06 | 2008-01-28 | Portela & Ca Sa | Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso. |
| AU2007346591A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of ADHD |
| WO2009014762A1 (en) | 2007-07-25 | 2009-01-29 | The Regents Of The University Of Colorado | Central administration of stable formulations of therapeutic agents for cns conditions |
| WO2009029308A1 (en) | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| US20110065674A1 (en) | 2008-05-14 | 2011-03-17 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| MX2011001384A (es) | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
| AU2011215870B2 (en) | 2010-02-09 | 2016-01-28 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2011143721A1 (en) | 2010-05-21 | 2011-11-24 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating neurodegenerative disorders |
-
2007
- 2007-03-30 AU AU2007346591A patent/AU2007346591A1/en not_active Abandoned
- 2007-03-30 WO PCT/AU2007/000421 patent/WO2008095221A1/en not_active Ceased
-
2008
- 2008-02-07 ES ES08700447T patent/ES2426764T3/es active Active
- 2008-02-07 WO PCT/AU2008/000154 patent/WO2008095253A1/en not_active Ceased
- 2008-02-07 JP JP2009548546A patent/JP5586962B2/ja not_active Expired - Fee Related
- 2008-02-07 EP EP12174063A patent/EP2505197A1/en not_active Withdrawn
- 2008-02-07 US US12/526,191 patent/US8957099B2/en not_active Expired - Fee Related
- 2008-02-07 EP EP08700447.9A patent/EP2129369B1/en not_active Not-in-force
-
2014
- 2014-07-23 JP JP2014149462A patent/JP2014196370A/ja active Pending
- 2014-12-30 US US14/586,081 patent/US9649297B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014196370A5 (https=) | ||
| ES2541528T3 (es) | Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma | |
| UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| EA201390772A1 (ru) | Новые соли и полиморфные формы афатиниба | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| AR085219A1 (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc | |
| EA201201661A1 (ru) | Новые аминопиразолохиназолины | |
| MX2014001088A (es) | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. | |
| AU2019268069A1 (en) | Methods and compositions for improving cognitive function | |
| CY1118813T1 (el) | Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| BR112014005389A8 (pt) | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
| EA201101674A1 (ru) | 2,4-диаминопиримидины, предназначенные для лечения заболеваний, характеризующихся избыточной или аномальной пролиферацией клеток | |
| CY1120094T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει despr036 eξenδinh-4(1-39)-lys6-nh2 για χρηση στην θεραπευτικη αγωγη μιας νευροεκφυλιστικης ασθενειας | |
| CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
| EA201590726A1 (ru) | Лахинимод для уменьшения таламического поражения при рассеянном склерозе | |
| MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
| CL2017000382A1 (es) | Compuestos bicíclicos sustituidos |